Mouse Vascular Endothelial cell Growth Factor D,VEGF-D ELISA kit

Code CSB-E07357m
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
c-fos induced growth factor (vascular endothelial growth factor D)
Alternative Names
Vegfd ELISA Kit; Figf ELISA Kit; Vascular endothelial growth factor D ELISA Kit; VEGF-D ELISA Kit; c-Fos-induced growth factor ELISA Kit; FIGF ELISA Kit
Abbreviation
Vegfd
Uniprot No.
Species
Mus musculus (Mouse)
Sample Types
serum, plasma, cell culture supernates, tissue homogenates
Detection Range
0.312 pg/mL-20 pg/mL
Sensitivity
0.078 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cardiovascular
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of mouse VEGF-D in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:100Average %95
Range %90-99
1:200Average %90
Range %85-96
1:400Average %96
Range %82-105
1:800Average %91
Range %85-99
Recovery
The recovery of mouse VEGF-D spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9088-94
EDTA plasma (n=4)9589-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
202.857 2.705 2.781 2.647
102.312 2.239 2.276 2.142
51.594 1.531 1.563 1.429
2.50.873 0.844 0.859 0.725
1.250.550 0.568 0.559 0.425
0.6250.341 0.344 0.343 0.209
0.3120.258 0.249 0.254 0.120
00.133 0.135 0.134  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

The mouse VEGFD ELISA Kit is engineered for accurate measurement of mouse VEGFD levels from samples including serum, plasma, or tissue homogenates. It uses the Sandwich-ELISA mechanism in combination with the enzyme-substrate chromogenic reaction to measure the mouse VEGFD content in the sample. The color intensity is positively correlated with VEGFD content in the sample. This kit has been validated against standards of sensitivity, specificity, precision, linearity, recovery, and lot-to-lot consistency.

VEGFD is a secreted protein that can promote the remodeling of blood vessels and lymphatics in development and disease. Through VEGFR, VEGFD is involved in various pathological processes, including inflammation, stenosis of vessels, wound healing, fetal growth retardation, obesity, cardiovascular disease, pulmonary disease, as well as transplantation/renal disease.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-3 (Flt4) receptor.
Gene References into Functions
  1. lymphangiogenesis is regulated by two distinct proteolytic mechanisms of ligand activation: one in which VEGFC activation by ADAMTS3 and CCBE1 spatially and temporally patterns developing lymphatics, and one in which VEGFD activation by a distinct proteolytic mechanism may be stimulated during inflammatory lymphatic growth PMID: 27159393
  2. This study uncovers a reciprocal relationship between dendrite geometry, the ability to generate nuclear calcium transients in response to synaptic inputs, and the subsequent induction of expression of plasticity-related and dendritic structure-preserving genes. Insufficient nuclear calcium signaling in CA1 hippocampal neurons and, consequently, reduced expression of the nuclear calcium target gene VEGFD. PMID: 28626015
  3. Overexpression of VEGFD causes lymphatic hyperplasia in lung, kidney, and brown adipose tissue. Overexpression of VEGFD in white adipose tissue causes a de novo lymphatic network. PMID: 27342876
  4. Vegf-d promotes oedema in response to hyperoxia in mice and support the hypothesis that VEGF-D signalling promotes vascular leak in human hyperoxic acute lung injury (HALI). PMID: 26924464
  5. VEGF-D may be beneficial in early-stage tumors since it suppresses the pro-tumorigenic inflammation, while at later stages VEGF-D-induced tumor lymphatics provide a route for metastasis. PMID: 27435926
  6. These results suggest that lymph node lymphangiogenesis occurs before metastasis in OSCC. VEGF-A and VEGF-D play critical roles in this process. PMID: 26630663
  7. Results provided evidence that IL-7/IL-7R induce VEGF-D upregulation and promote lymphangiogenesis via c-Fos/c-Jun pathway in lung cancer. PMID: 24115038
  8. Epidermal keratinocyte proliferation in vitro was not affected by VEGF-C or VEGF-D. PMID: 23695550
  9. Neutrophils contribute to lymphangiogenesis primarily by modulating VEGF-A bioavailability and bioactivity and, to a lesser extent, secreting VEGF-D. Neutrophils increased VEGF-A bioavailability and bioactivity via the secretion of MMP9 and heparanase. PMID: 24113869
  10. Vegf-d deficiency alters the caliber of initial lymphatics in the dermis leading to reduced functional capacity. PMID: 23439394
  11. Vascular endothelial growth factor-C and -D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction. PMID: 22932121
  12. VEGF-D has a role in progestin-induced break-through bleeding in thin-walled blood and lymphatic endometrial vessels PMID: 22383980
  13. nuclear calcium-VEGFD signaling mediates the effect of neuronal activity on the maintenance of dendritic arbors in the adult hippocampus and is required for cognitive functioning. PMID: 21745642
  14. Data show that that OUBC induces profound lymphangiogenesis in the tumor and SLN and substantial lymphatic metastasis to SLN through VEGF-C/D-VEGFR-3 signaling pathway. PMID: 21481239
  15. VEGF-D over-expression has differential effects on the uterine vasculature. These effects may facilitate VEGF-D's ability to promote endometrial cancer metastasis and disease progression. PMID: 20615255
  16. We investigated the expression of IEGs, including c-fos, fos-B, c-jun and dusp-1 mRNA, in the mouse heart after a once-daily methamphetamine injection for 1day, 2 or 4weeks. PMID: 19828354
  17. These results show that VEGF-C/-D together with its receptor VEGFR-3 provides an auto-/paracrine growth and chemotactic system for glial precursors in the developing brain. PMID: 19646499
  18. there are unique temporal and spatial expressions of VEGF-D isoforms during lung development which related factors have distinct functions in vascular and lymphatic patterning of the lung PMID: 12112468
  19. VEGF-D promotes tumor angiogenesis, lymphangiogenesis and metastatic spread by a paracrine mechanism PMID: 12148568
  20. study demonstrated that beta-catenin negative regulation is on theessenger vascular endothelial growth factor-D mRNA 3'-untranslated region PMID: 12920128
  21. VEGF-C and VEGF-D are ligands for the integrin alpha9beta1 PMID: 15590642
  22. The lack of a profound lymphatic phenotype in Vegf-d-deficient mice suggests that Vegf-d does not play a major role in lymphatic development. PMID: 15743836
  23. VEGF-D/VEGFR-3 signaling plays a critical role in osteoblast maturation PMID: 16624815
  24. results suggest the presence of lymphatic capillaries throughout the skeletal muscle, and present the localisation of VEGF-C and -D in the muscles. PMID: 16924525
  25. in binding VEGFR-2, furin and PC5 promote cleavage of N-and C-terminal VEGF-D propeptides, whereas PC7 promotes cleavage of the C-terminal propeptide only PMID: 17242158
  26. Diabetes increased the expression of VEGF-D in skeletal muscle. VEGF-D levels were not changed either in healthy or in diabetic muscle after the exercise training. PMID: 17766486
  27. The expression of VEGF-D in the marginal portion of tumor significantly associated with lymphatic metastasis and prognosis in patients with pancreatic adenocarcinoma and may induced lymphangiogenesis. PMID: 18061373
  28. Expression of VEGF-D is involved in growth and lymphatic spread of HCC. Therefore, VEGF-D might represent a therapeutic target in HCC. PMID: 18338756
  29. These results suggest VEGF-C- and VEGF-D-independent functions for VEGFR-3 in the early embryo. PMID: 18519586
  30. These data do not support an important role of VEGF-D in (lymph) angiogenesis or in adipose tissue development. PMID: 19022221
  31. VEGF-C, -D, and -A derived from the CD11b+/Gr-1+ macrophages and local inflamed tissues play a critical role in promoting antigen clearance and inflammation resolution. PMID: 19346498
  32. Long-term expression of VEGF-C and VEGF-D in skeletal muscle results in the generation of new functional blood and lymphatic vessels. PMID: 19443835

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
PDGF/VEGF growth factor family
Tissue Specificity
Highly expressed in fetal and adult lung.
Database Links
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1